Uncategorized 30 Apr 2025 European Immunization Week 2025: Humanly possible Under the theme “Immunization for all is Humanly Possible”, this year’s campaign highlights the urgent need to achieve high and… Pantitra Laohatranon
Uncategorized 11 Apr 2025 New Research Boosts Future Whooping Cough Vaccines Whooping cough, or pertussis, was once a leading cause of death for children in the U.S. and worldwide before the… Pantitra Laohatranon
Uncategorized 20 Jul 2023 Effective and safe transfer of maternal antibodies persisting two months postpartum following maternal immunization with different doses of recombinant pertussis-containing vaccines Effective and safe transfer of maternal antibodies persisting two months postpartum following maternal immunization with different doses of recombinant pertussis-containing… Pantitra Laohatranon
Uncategorized 11 Jul 2023 A phase 2 randomized controlled dose-ranging trial of recombinant pertussis booster vaccines containing genetically inactivated pertussis toxin in pregnant women A phase 2 randomized controlled dose-ranging trial of recombinant pertussis booster vaccines containing genetically inactivated pertussis toxin in pregnant women… Pantitra Laohatranon
Uncategorized 01 Apr 2022 A phase 2 randomized controlled dose-ranging trial of recombinant pertussis booster vaccines containing genetically inactivated pertussis toxin in women of childbearing age A phase 2 randomized-controlled safety and immunogenicity trial evaluating different doses of recombinant acellular pertussis vaccine containing genetically-inactivated pertussis toxin… Pantitra Laohatranon
Uncategorized 20 Jul 2021 Antibody persistence 2 and 3 years after booster vaccination of adolescents with recombinant acellular pertussis monovalent aPgen or combined TdaPgen vaccines Recombinant pertussis vaccines inducing long-lasting immune responses could help to control the rise in pertussis. We here report on persisting antibody responses 2 and 3 years after booster vaccination with a new generation recombinant acellular pertussis vaccine. Antibody persistence 2 and 3 years after booster vaccination of adolescents with recombinant acellular pertussis monovalent aPgen or combined TdaPgen… Pantitra Laohatranon
Uncategorized 07 Jul 2021 Antibody persistence 2 and 3 years after booster vaccination of adolescents with recombinant acellular pertussis monovalent aPgen or combined TdaPgen vaccines Recombinant pertussis vaccines inducing long-lasting immune responses could help to control the rise in pertussis. We here report on persisting… Pantitra Laohatranon
Uncategorized 03 Dec 2020 Enhanced post-licensure safety surveillance of a new recombinant acellular pertussis vaccine licensed as a monovalent (aP, Pertagen®) and tetanus, reduced-dose diphtheria combination (TdaP, Boostagen®) vaccine for immunization of adolescents and adults in Thailand A new generation of recombinant acellular pertussis vaccine containing genetically inactivated pertussis toxin (PTgen) was licensed as a monovalent pertussis… Pantitra Laohatranon
